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Objectives: Two randomized Phase I studies in separate populations of healthy adult volunteers inves-
tigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin
w; Novartis Pharma AG,
Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative to the currently licensed
30 min iv infusion.
Methods: Study 1 was an open-label, single-dose, two-period, crossover study in which each subject
received 6 mg/kg daptomycin administered as a 30 min iv infusion (n515) and as a 2 min iv injection
(n516). In Study 2, a single-blind, multiple-dose, parallel-group study, subjects received a once-daily
2 min iv injection of 6 mg/kg daptomycin (n512), 4 mg/kg daptomycin (n58) or placebo (n54) for
7 days. Single-dose pharmacokinetics were assessed at various timepoints up to 36 and 24 h post-
dose in Study 1 and Study 2, respectively, and multiple-dose pharmacokinetics were assessed in
Study 2 at day 7 for 48 h post-dose.
Results: In Study 1, pharmacokinetic comparability between the two administration regimens was
demonstrated by meeting the bioequivalence criteria for the exposure parameters, AUC0–t, AUC0–1
and Cmax. In Study 2, time-invariant pharmacokinetic properties as well as dose-proportional pharma-
cokinetics were demonstrated for the daptomycin 2 min iv injection regimen. In both studies, daptomy-
cin was well tolerated and the majority of treatment-emergent adverse events were of mild intensity
and considered to be unrelated to daptomycin.
Conclusions: The similar pharmacokinetic and safety proﬁles of the two administration regimens
suggest that the 2 min iv injection may be a convenient treatment option for both patients and health-
care professionals.
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Introduction
Daptomycin (Cubicin
w; Novartis Pharma AG, Basel, Switzerland)
is an antibacterial agent indicated for the treatment of complicated
skin and soft tissue infections (cSSTIs) caused by susceptible
strains of Gram-positive microorganisms. Additionally, daptomy-
cin is approved for the treatment of Staphylococcus aureus blood-
stream infections (bacteraemia), including those with right-sided
infective endocarditis (RIE) in the USA, and in the European
Union for RIE due to S. aureus and S. aureus bacteraemia when
associated with RIE or with cSSTI.
1,2
Daptomycin has rapid, concentration-dependent bactericidal
activity against clinically relevant Gram-positive bacteria includ-
ing methicillin-resistant S. aureus (MRSA). The potency of dap-
tomycin against S. aureus has remained consistent throughout
7 years of surveillance studies (2001–2007) in both North
America and Europe.
3–9
The currently approved method of administration for dapto-
mycin is as a once-daily 30 min intravenous (iv) infusion, and
the efﬁcacy, safety and pharmacokinetics of this dosing regimen
have been established in healthy subjects
10,11 as well as in
patients with Gram-positive infections.
12 In Phase III clinical
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patients were of mild or moderate intensity and not attributed to
the study drug.
13,14 Daptomycin pharmacokinetics are linear
after the administration of single or multiple doses of up to
12 mg/kg by 30 min iv infusion, with a t1/2 of  8 h; steady state
is reached by day 3, independent of dose.
10 Daptomycin has a
low volume of distribution (V; averaging  0.1 L/kg) and is
90–93% protein bound, independent of the daptomycin concen-
tration.
10 Renal excretion is the major elimination pathway;
urinary recovery over a 24 h period ranges from  34% to  68%
of the administered dose in healthy subjects.
15–17
Administration of antibiotics by rapid injection is attractive
because of advantages over infusion such as cost-effectiveness,
greater ﬂexibility in the management of ﬂuid balance and suit-
ability for administration as outpatient parenteral antibiotic
therapy.
18 This paper presents the results from two clinical
studies that evaluated the pharmacokinetics, safety and tolerabil-
ity of daptomycin administered as a 2 min iv injection, com-
pared with a 30 min iv infusion in healthy adult volunteers.
Materials and methods
Study designs
Study 1 was a randomized, open-label, single-dose, two-period,
crossover study. Each subject received 6 mg/kg daptomycin admi-
nistered as a 30 min iv infusion and as a 2 min iv injection. The
order of administration was randomized and each dose was separated
by a washout period of 5 days.
Study 2 was a randomized, single-blind, multiple-dose, parallel-
group, placebo-controlled study. Subjects were randomized in a
3:2:1 ratio to receive 6 mg/kg daptomycin, 4 mg/kg daptomycin or
placebo administered as a 2 min iv injection once daily for 7 days.
For both studies, the 2 min iv injection was administered by per-
ipheral iv administration using a Medex Medfusion 3010a (Medex
Inc., Duluth, GA, USA) or equivalent syringe driver. The 30 min iv
infusion was administered using a Graseby 500 Modular Infusion
Pump (Smiths Medical International Ltd, Watford, UK).
Both studies were approved in the UK by the South Wales
Research Ethics Committee and all study participants provided
written informed consent. Studies were performed at Simbec
Research Ltd, Merthyr Tydﬁl, South Wales, UK, and were conducted
in accordance with the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use, good clinical practice and local regulatory requirements.
Study population
Healthy men and women, between 18 and 45 years of age, were eli-
gible to participate in the study, provided they had an estimated
CLCR rate .70 mL/min for Study 1 or .80 mL/min for Study 2
(based on the Cockcroft–Gault equation). The permitted body mass
index was 20–30 kg/m
2 (inclusive), with a permissible body weight
of 50–80 kg for women and 60–90 kg for men. Female volunteers
were required to have a negative serum pregnancy test result at
screening and admission (day 1).
Subjects with any personal or family history of adverse drug
reaction, hypersensitivity to daptomycin or drugs with a similar
chemical structure or any serious allergy were excluded from the
study. Additional exclusion criteria included serum creatine phos-
phokinase  1.5 of the upper limit of normal and any signiﬁcant
clinical or laboratory abnormality.
Pharmacokinetic analysis
Sample collection. Whole blood samples were collected into lithium
heparin tubes. In Study 1, samples were collected before dosing,
immediately after dosing and at 15 min, 30 min and 1, 1.5, 2, 4, 6,
8, 12, 24 and 36 h from the end of the dosing period. For subjects
receiving the 30 min iv infusion, an additional sample was collected
15 min after the start of infusion.
In Study 2, blood samples were collected before dosing, immedi-
ately after dosing, at 15 and 30 min after the start of the 2 min iv
injection and at 1, 2, 4, 6, 8, 12 and 24 h after the start of the injec-
tion on days 1 and 7. Additional samples were obtained at 36 and
48 h after the 2 min iv injection on day 7, and a trough sample was
obtained before dosing on days 4 and 6. Urine samples were pooled
from collections obtained pre-dosing and at the following intervals
from the start of administration of the 2 min iv injection: 0–12 and
12–24 h on day 1; and 0–12, 12–24 and 24–48 h on day 7.
Plasma and urine daptomycin concentrations. Total plasma and
urine daptomycin concentrations were analysed according to a vali-
dated HPLC detection method.
11 The lower limit of quantiﬁcation
was 3 mg/L and the upper limit was 500 mg/L. The precision and
sensitivity of these assays were within previously determined ranges.
Non-compartmental analysis. Relevant pharmacokinetic parameters
(e.g. AUC, CL, Cmax, Tmax, t1/2 and V) for daptomycin were calcu-
lated using non-compartmental methods implemented in SAS
w soft-
ware (version 9.1, SAS Institute, Cary, NC, USA). The trapezoidal
rule was used to calculate AUC from time zero to the last measur-
able concentration (AUC0–t). AUC0–1 was estimated using the tra-
pezoidal rule, with the terminal elimination rate constant (beta)
being estimated using log-linear regression of the terminal segment
of the concentration–time curve.
In Study 1, statistical analysis was carried out on log-
transformed, dose-normalized pharmacokinetic parameters, using an
ANOVA model suited to a two-period, two-treatment, two-sequence
crossover design. Least square means were estimated and back trans-
formed to provide point estimates and 95% conﬁdence intervals
(CIs) for the ratio of the 2 min iv injection to the 30 min iv infusion
for each parameter. Period and sequence effects were evaluated at
the two-sided 5% level.
In Study 2, analysis of accumulation ratio, dose proportionality,
assessment of steady state and comparison of day 1 and day 7 phar-
macokinetic parameters were carried out.
Compartmental analysis. Pharmacokinetic modelling used to
describe the serum daptomycin concentrations was based on a two-
compartment, linear disposition model. The population pharmacoki-
netic model was ﬁtted using the ﬁrst-order conditional estimation
method with interaction, as implemented in NONMEM software
(version V level 1.1).
19
The parameters ﬁtted were CL, central compartment volume of
distribution (Vc), peripheral compartment volume of distribution
(Vt), distribution clearance (CLd) and duration of infusion (D1).
Individual pharmacokinetic parameters (e.g. CLi) were assumed to
be log-normally distributed (the subscript i denotes the ith individ-
ual). The parameter was modelled as follows:
CL ¼ uCL   expðhCLi
i Þ
where uCL is the population mean clearance and hi
CLi are random
effects reﬂecting the deviation of the logarithm of individual CL from
the logarithm of the population mean value. hi
CLi was assumed to be
normally distributed with mean zero and variance vCL. Other pharma-
cokinetic parameters were similarly modelled. Inter-individual effects
were assumed to be independent of each other.
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Treatment-emergent AEs included all AEs occurring after the ﬁrst
dose of study medication. AEs were categorized by the investigator
as not related, unlikely to be related, possibly related or probably
related to the study drug. The severity of each AE was also deter-
mined by the investigator as mild, moderate or severe. The ﬁnal
post-study follow-up took place between 1 and 11 days after the last
dose of study medication for Study 1 and between 9 and 11 days
after last dosing for Study 2.
Results
Study populations
Sixteen subjects (eight males) were enrolled in the single-dose
(6 mg/kg) crossover study (Study 1). The mean age (+SD)
was 26.3+7.2 years, with a mean weight (+SD) of
71.98+10.90 kg. Fifteen subjects were Caucasian and one was
of mixed race. Fifteen subjects received both the 2 min iv injec-
tion and the 30 min iv infusion and did not experience any sig-
niﬁcant AEs. One subject received only the 2 min iv injection
and was excluded from the safety analyses for the infusion and
from all pharmacokinetic analyses (details in the safety analysis).
For Study 2, 24 subjects (21 males) were randomized to
receive 6 mg/kg daptomycin (n¼12), 4 mg/kg daptomycin (n¼8)
or placebo (n¼4) administered as a 2 min iv injection once
daily for 7 days. All subjects were Caucasian. The mean age
and weight (+SD) of subjects were: 29.3+8.6 years and
74.79+13.92 kg, respectively, for the 6 mg/kg daptomycin
group; 27.8+6.3 years and 81.99+1.14 kg, respectively, for
the 4 mg/kg daptomycin group; and 29.8+7.3 years and
78.13+6.60 kg, respectively, for the placebo group. The pharma-
cokinetic population consisted of the 20 subjects receiving dapto-
mycin, and all subjects were included in the safety analyses.
Pharmacokinetic analysis
Comparison of the daptomycin 2 min iv injection and 30 min iv
infusion (Study 1). The mean plasma concentration–time proﬁles
following a single 6 mg/kg dose of daptomycin were similar,
whether daptomycin was administered as a 2 min iv injection or
as a 30 min iv infusion (Figure 1a).
Pharmacokinetic parameters following administration of dap-
tomycin as a 2 min iv injection or a 30 min iv infusion are sum-
marized in Table 1. There were no signiﬁcant differences in
AUC or Cmax between the 2 min iv injection and the 30 min iv
infusion of daptomycin, and all 95% CIs fell within the com-
monly used 80%–125% equivalence range. All other pharmaco-
kinetic parameters were similar for the two regimens, including
small values for mean V.
Daptomycin pharmacokinetics following single and multiple
doses of the 2 min iv injection (Study 2). The mean plasma
concentration–time proﬁles following single and multiple doses
of the daptomycin 2 min iv injection are shown in Figure 1(b
and c); individual pharmacokinetic parameter estimates are sum-
marized in Table 2. Peak plasma concentrations were observed
at the ﬁrst or second sampling time (2 or 15 min after the start
of the 2 min iv injection). Mean plasma concentration–time pro-
ﬁles for the 6 mg/kg daptomycin and 4 mg/kg daptomycin
treatment groups were clearly separable. For each dose of dapto-
mycin, all pharmacokinetic parameters were similar on day 1
and on day 7, with the exception of a small increase in Tmax on
day 7 compared with day 1. Steady-state concentrations of
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Figure 1. Mean daptomycin concentration–time plots for daptomycin
administered as a 2 min iv injection or as a 30 min iv infusion (Study 1; a),
and following single and multiple doses of the daptomycin 2 min iv injection
(Study 2; b and c). Data shown are means+SD.
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153daptomycin were achieved by the third daily dose for both treat-
ment groups (data not shown).
Single-dose pharmacokinetics (measured on day 1) and
multiple-dose pharmacokinetics (measured on day 7) showed dose
proportionality between the 6 mg/kg daptomycin and 4 mg/kg
daptomycin doses. All 95% CIs, for the ratio of means of the phar-
macokinetic parameters, fell within the 80%–125% equivalence
range with the exception of dose-normalized Ae0–tau on days 1
and 7 and dose-normalized Cmax on day 1 (Table 3). For both
treatment groups, CL was unchanged between day 1 and day 7. A
small accumulation of daptomycin with repeated doses was indi-
cated by the ratio, for day 1 versus day 7, of .1 for both AUC0–
tau and Ae0–tau [Table S1, available as Supplementary data at JAC
Online (http://jac.oxfordjournals.org/)].
Compartmental pharmacokinetics of daptomycin.
Pharmacokinetic parameters were estimated precisely and diagnos-
tic plots from the daptomycin pharmacokinetic model showed a
good ﬁt of the ﬁnal model to the observed daptomycin plasma
concentrations [Figure S1, available as Supplementary data at
JAC Online (http://jac.oxfordjournals.org/)]; population parameter
estimates are presented in Table S2 [available as Supplementary
data at JAC Online (http://jac.oxfordjournals.org/)]. Additional
analyses were conducted to compare Cmax predicted by the
above model for the 2 min iv injection with that of the 30 min iv
infusion of 6 mg/kg daptomycin. The predicted Cmax after
administration of a single 6 mg/kg daptomycin dose as 2 min iv
injection and 30 min iv infusion were 86.6 mg/L and 76.4 mg/L,
respectively.
Table 2. Pharmacokinetic parameters following a single dose or multiple doses of the daptomycin 2 min iv injection in healthy adult
volunteers (Study 2)
Day 1 Day 7
daptomycin
6 mg/kg
n¼12
mean (SD)
daptomycin
4 mg/kg
n¼8
mean (SD)
daptomycin
6 mg/kg
n¼12
mean (SD)
daptomycin
4 mg/kg
n¼8
mean (SD)
AUC0–1 (mg.h/L) 690.37 (68.83) 468.40 (98.90) NA NA
AUC0–tau (mg.h/L) NA NA 701.08 (81.96) 475.24 (70.97)
Cmax (mg/L) 97.49 (17.30) 56.80 (8.32) 91.83 (17.88) 62.83 (11.31)
Tmax (h)
a 0.03 (0.03–0.25) 0.14 (0.03–0.25) 0.25 (0.03–0.25) 0.25 (0.03–0.25)
t1/2 (h) 8.43 (0.63) 9.08 (0.94) 8.65 (0.63) 8.93 (1.05)
CL (L/h/kg) 0.0088 (0.0009) 0.0090 (0.0025) 0.0087 (0.001) 0.0086 (0.001)
V (L/kg) 0.106 (0.011) 0.116 (0.031) 0.107 (0.011) 0.109 (0.011)
%Fe0–tau 56.74 (12.25) 54.31 (12.30) 65.06 (9.81) 67.52 (12.66)
AUC0–tau, area under the plasma concentration–time curve over the dosing interval; %Fe0–tau, percentage of daptomycin excreted unchanged in the urine
over 24 h; NA, not applicable.
Means are arithmetic means of non-transformed values.
aMedian (range).
Table 1. Comparison of pharmacokinetic parameters in healthy adult volunteers following a single 6 mg/kg
dose of daptomycin administered as a 2 min iv injection relative to a 30 min iv infusion (Study 1)
2 min iv injection
n¼15
mean (SD)
30 min iv infusion
n¼15
mean (SD) 95% CI
CL (L/h/kg) 0.0089 (0.0012) 0.0083 (0.0008) NA
t1/2 (h) 8.7 (1.0) 8.7 (0.9) NA
V (L/kg) 0.113 (0.014) 0.105 (0.012) NA
Cmax (mg/L) 94.7 (22.6) 88.4 (12.4) 0.9588–1.1719
AUC0–t (mg.h/L) 626.5 (103.4) 669.6 (69.1) 0.8709–1.0055
AUC0–1 (mg.h/L) 691.4 (96.0) 725.2 (63.3) 0.9007–1.0117
AUC0–t, area under the plasma concentration–time curve from time zero to the last measurable concentration; NA, not
applicable; V, volume of distribution based on the terminal phase.
The table shows the arithmetic means of non-transformed values, except for t1/2, where the harmonic mean is shown.
CIs are for the ratio of the geometric means derived from the ANOVA of log-transformed values.
Parameters were not dose-normalized.
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degrees of renal impairment, renal function affected the differ-
ences in peak daptomycin exposure between the two regimens,
Cmax was predicted based on clearance from the current pharma-
cokinetic model re-parameterized using the previously described
relationship between daptomycin CL with estimated CLCR:
12
0:011 þ 0:00514ðCLCR   91:2Þ=60
with all other pharmacokinetic parameters unchanged. The pre-
dicted Cmax values (estimated at 0 h post-dose) for subjects with
CLCR of 80, 50 and 30 mL/min were 86.57, 86.62 and
86.66 mg/L, respectively, for the 2 min iv injection and 76.58,
77.13 and 77.5 mg/L, respectively, for the 30 min iv infusion.
These data suggest a small (,15%) increase in Cmax for the
2 min iv injection compared with the 30 min iv infusion, irre-
spective of the renal function status of the patients.
Safety and tolerability
Safety of the 2 min injection versus 30 min infusion in a single-
dose, crossover trial (Study 1). Treatment with daptomycin was
well tolerated with no consistent differences between treatment
groups in the type of AEs reported. A total of 21 AEs were
reported by 9 of 16 subjects. Nineteen AEs were of mild sever-
ity and no serious or severe AEs or deaths were reported during
the study. Six subjects reported AEs that were considered to be
possibly related to the study medication, four subjects following
administration of the daptomycin 2 min iv injection and two
subjects following administration of the daptomycin 30 min iv
infusion (Table 4). Local tolerability reactions were mild tender-
ness (one subject in the 2 min iv injection group and two sub-
jects in the 30 min iv infusion group) and pain (one subject in
the 30 min iv infusion group).
One subject discontinued prematurely due to an AE
(anaemia) not related to study medication after completing the
2 min iv injection treatment period and before receiving the
30 min iv infusion. The anaemia was mild and resolved after
3 weeks. No other clinically signiﬁcant haematological changes
were reported for any other subject during the study.
Safety after single and multiple doses of 6 mg/kg daptomycin,
4 mg/kg daptomycin or placebo administered as a 2 min iv
injection once daily for 7 days (Study 2). No clinically relevant
differences in AEs and local tolerability were observed between
daptomycin-treated and placebo-treated subjects. A total of 25
AEs were reported by 14 of 24 subjects enrolled on the
multiple-dose study. The majority of AEs were of mild intensity,
and there were no serious or other signiﬁcant AEs. A total of
ﬁve subjects treated with daptomycin and four subjects treated
with placebo reported AEs that were considered to be possibly
related to the study medication (Table 5). No AE led to withdra-
wal from the study. One subject in the 6 mg/kg daptomycin
group experienced ﬁrst-degree atrioventricular block, associated
with a congenital wandering pacemaker, and not considered
related to daptomycin treatment.
Table 3. Ratio of geometric mean pharmacokinetic parameters for
the 6 mg/kg (n¼12) and 4 mg/kg (n¼8) doses of daptomycin
administered as a 2 min iv injection to healthy adult volunteers
(Study 2)
Ratio of 6 mg/kg:4 mg/kg
daptomycin (95% CI)
day 1 day 7
AUC0–tau (dose-normalized) 1.02 (0.87–1.2) 0.99 (0.87–1.12)
CL 1.00 (0.85–1.18) 1.01 (0.9–1.15)
Cmax (dose-normalized) 1.14 (0.97–1.3) 0.97 (0.82–1.16)
Ae0–tau (dose-normalized) 0.95 (0.72–1.25) 0.88 (0.69–1.11)
Ae0–tau, cumulative amount of unchanged daptomycin excreted in urine;
AUC0–tau, area under the plasma concentration–time curve over the dosing
period.
Table 4. Adverse events possibly or probably related to study drug following a 6 mg/kg dose of daptomycin
administered as a 2 min iv injection or as a 30 min iv infusion (Study 1)
Adverse event (system organ class)
Subjects with at least one adverse event, n (%)
2 min iv injection
n¼16
30 min iv infusion
n¼15
Any adverse event 4 (25) 2 (13)
Gastrointestinal disorders 1 (6) 0
nausea 1 (6) 0
General disorders and administration-site conditions 1 (6) 0
fatigue 1 (6) 0
Infections and infestations 1 (6) 2 (13)
urinary tract infection 1 (6) 2 (13)
Nervous system disorders 1 (6) 0
headache 1 (6) 0
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all reactions were generally mild and transient, resolving within
1 h. Nine subjects experienced erythema: two subjects in the
6 mg/kg daptomycin group; ﬁve subjects in the 4 mg/kg dapto-
mycin group; and two subjects in the placebo group.
Discussion
These studies demonstrate that daptomycin exposure (including
AUC and Cmax) is similar, whether it is administered as a 2 min
iv injection or the currently approved 30 min iv infusion, and is
consistent with the results of previous studies with the 30 min iv
infusion in healthy volunteers.
10,14,17,20 In addition, the percen-
tage of daptomycin excreted unchanged in the urine over 24 h
(measured on day 7) was within the 34%–68% range of pre-
viously reported studies,
10,17,20 conﬁrming renal excretion as the
major elimination pathway for daptomycin.
For additional rigor, and because it is often difﬁcult to
capture true Cmax from observed concentration–time data fol-
lowing rapid iv injection, pharmacokinetic modelling was also
employed. This predicted a Cmax slightly (,15%) higher follow-
ing the 2 min iv injection of daptomycin compared with the
approved 30 min iv infusion regimen, irrespective of modelled
differences in renal function. This potential increase in Cmax is
not expected to change the safety proﬁle of the currently
approved doses of daptomycin. The pharmacokinetic, safety and
tolerability proﬁles of daptomycin have been investigated in
clinical trials, with single daily daptomycin doses of up to
12 mg/kg, exposing subjects to substantially higher Cmax than
the levels observed from the 6 mg/kg daptomycin 2 min iv injec-
tion. High-dose daptomycin (8, 10 and 12 mg/kg) administered
as a 30 min iv infusion,
10 resulted in Cmax values equivalent to
112%, 137% and 174% of that observed with the 6 mg/kg 2 min
iv injection in Study 1, respectively. Furthermore, no signiﬁcant
AEs were observed in subjects receiving these high doses once
daily for up to 14 days.
10 Indeed, the present studies suggest that
daptomycin administered as a 2 min iv injection has a similar
safety proﬁle to that of the 30 min iv infusion, with no new or
unexpected safety concerns. The majority of treatment-emergent
AEs were mild and not considered to be related to daptomycin
treatment, and local tolerability reactions were similar between
daptomycin-treated and placebo-treated subjects.
As a concentration-dependent bactericidal antibiotic, the efﬁ-
cacy of daptomycin is pharmacodynamically best correlated with
the AUC/MIC or Cmax/MIC ratio.
21 Given that AUCs were similar
following the different modes of administration, and that Cmax was
predicted to be slightly higher with the 2 min iv injection, the efﬁ-
cacy of the 2 min daptomycin iv injection is expected to be
similar to that of the standard 30 min iv infusion.
The daptomycin 2 min iv injection has the potential to confer
a number of beneﬁts in the management of patients with serious
Gram-positive infections. As well as simplifying the dosing
schedule for patients receiving multiple medications via catheter,
the reduced administration volume gives the physician more
scope in managing the patient’s ﬂuid balance, which may be a
particular concern for patients in intensive care units.
22
Additionally, the increased risk of catheter-related bloodstream
infections associated with the use of multilumen catheters
23
suggests that drugs that can be administered relatively rapidly
have the potential to decrease the need for such catheters,
thereby reducing the risk of infection.
Patients with serious Gram-positive infections are increas-
ingly treated in the outpatient setting.
15,16 Treating patients with
serious infections, such as MRSA, as outpatients, reduces the
risk of spreading infections to other hospital patients. Agents
Table 5. Adverse events possibly or probably related to study drug following multiple doses of daptomycin
2 min iv injection or placebo (Study 2)
Adverse event (system organ class)
Subjects with at least one adverse event, n (%)
daptomycin
6 mg/kg
n¼12
daptomycin
4 mg/kg
n¼8
placebo
n¼4
Any adverse event 3 (25) 2 (25) 4 (100)
Gastrointestinal disorders 0 1 (13) 1 (25)
ﬂatulence 0 1 (13) 0
nausea 0 0 1 (25)
Infections and infestations 0 0 1 (25)
upper respiratory tract infection 0 0 1 (25)
Musculoskeletal, connective tissue and bone disorders 0 1 (13) 0
pain in extremity 0 1 (13) 0
Nervous system disorders 3 (25) 1 (13) 2 (50)
dizziness 1 (8) 0 0
dizziness postural 1 (8) 0 0
headache 1 (8) 0 1 (25)
lethargy 0 1 (13) 0
paraesthesia 0 0 1 (25)
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156that can be administered by slow iv injection may be advan-
tageous in this context, because they obviate the need for infu-
sion devices,
18 which may incur additional costs. Indeed, short
injections have been shown to be one of the most cost-effective
methods of administering iv drugs in the outpatient setting,
24
and are more convenient for patients in that they minimize the
degree of disruption to everyday activities.
These data indicate that daptomycin, administered as a 2 min
iv injection once daily over 7 days, has a similar safety, toler-
ability and pharmacokinetic proﬁle to that of the 30 min iv infu-
sion. The 2 min iv injection may, therefore, offer an alternative
method of administration to the currently approved 30 min iv
infusion. This could contribute towards more streamlined man-
agement of seriously ill patients in hospital and simplify treat-
ment administration for patients and caregivers, thus facilitating
the potential use of daptomycin in the outpatient setting.
Additional studies in patients are warranted to conﬁrm the prom-
ising results observed in healthy volunteers.
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